Survival Outcomes of Patients With Borderline Resectable and Resectable Pancreatic Adenocarcinoma Treated With Neoadjuvant Short-Course Chemoradiotherapy With Capecitabine-Based vs. Gemcitabine-Based Concurrent Chemotherapy

被引：0
|
作者：
Neibart, S. S. [1 ]
Mamidanna, S. [1 ]
Chundury, A. [1 ]
Sayan, M. [1 ]
Alexander, H. R. [2 ]
August, D. [2 ]
Berim, L. D. [3 ]
Boland, P. M. [3 ]
Grandhi, M. S.
Gulhati, P. [3 ]
Hochster, H. S. [3 ]
Kennedy, T. J. [2 ]
Langan, R. C. [2 ]
Spencer, K. [3 ]
Jabbour, S. K. [1 ]
机构：
[1] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA
[2] Rutgers Canc Inst New Jersey, Dept Surg Oncol, New Brunswick, NJ USA
[3] Rutgers Canc Inst New Jersey, Dept Med Oncol, New Brunswick, NJ USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2081
引用
收藏
页码：E64 / E64
页数：1
相关论文
共 50 条
  • [31] A randomized phase II trial of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: Gemcitabine alone vs. gemcitabine combined with cisplatin.
    Palmer, DH
    Stocken, DD
    Buckels, JAC
    Hewitt, H
    Markham, CE
    Mirza, D
    Johnson, PJ
    Hassan, AB
    Bramhall, SR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 367S - 367S
  • [32] Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer
    Esnaola, Nestor F.
    Chaudhary, Uzair B.
    O'Brien, Paul
    Garrett-Mayer, Elizabeth
    Camp, E. Ramsay
    Thomas, Melanie B.
    Cole, David J.
    Montero, Alberto J.
    Hoffman, Brenda J.
    Romagnuolo, Joseph
    Orwat, Kelly P.
    Marshall, David T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04): : 837 - 844
  • [33] Induction gemcitabine-based chemotherapy and neoadjuvant stereotactic body radiation therapy achieve high margin-negative resection rates for borderline resectable pancreatic cancer
    Chuong, Michael D.
    Springett, Gregory M.
    Weber, Jill
    Klapman, Jason
    Vignesh, Shivakumar
    Hodul, Pamela J.
    Malafa, Mokenge P.
    Leuthold, Susan
    Hoffe, Sarah E.
    Shridhar, Ravi
    JOURNAL OF RADIATION ONCOLOGY, 2012, 1 (03) : 273 - 281
  • [34] Effect of neoadjuvant chemoradiotherapy (nCRT) on survival in patients with borderline resectable (BR) pancreatic adenocarcinoma (PDA) with acceptable peri-operative morbidity
    Minter, Rebecca Manget
    Feng, Mary Uan-Sian
    Al-Hawary, Mahmoud
    Shen, Jincheng
    Schipper, Matthew J.
    Bednar, Filip
    Proctor, Erica
    Warner, Susanne Gray
    Zalupski, Mark M.
    Simeone, Diane M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] Phase I trial of short-course chemoradiotherapy followed by chemotherapy as total neoadjuvant therapy for patients with potentially resectable gastric cancer.
    Badgwell, Brian D.
    Das, Prajnan
    Ikoma, Naruhiko
    Murphy, Mariela A. Blum
    Li, Jenny Jing
    Estrella, Jeannelyn
    Minsky, Bruce D.
    Mansfield, Paul F.
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 362 - 362
  • [36] ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy Changes Body Composition Influencing Long-term Outcomes
    Takaichi, Shohei
    Tomimaru, Yoshito
    Kobayashi, Shogo
    Toya, Keisuke
    Sasaki, Kazuki
    Iwagami, Yoshifumi
    Yamada, Daisaku
    Noda, Takehiro
    Takahashi, Hidenori
    Asaoka, Tadafumi
    Tanemura, Masahiro
    Doki, Yuichiro
    Eguchi, Hidetoshi
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 2469 - 2470
  • [37] ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy Changes Body Composition Influencing Long-term Outcomes
    Shohei Takaichi
    Yoshito Tomimaru
    Shogo Kobayashi
    Keisuke Toya
    Kazuki Sasaki
    Yoshifumi Iwagami
    Daisaku Yamada
    Takehiro Noda
    Hidenori Takahashi
    Tadafumi Asaoka
    Masahiro Tanemura
    Yuichiro Doki
    Hidetoshi Eguchi
    Annals of Surgical Oncology, 2023, 30 : 2469 - 2470
  • [38] Neoadjuvant Chemotherapy With Chemoradiotherapy for Patients With Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma- Retrospective Review From a Tertiary Care Hospital
    Nerwal, Avtaj
    Yip, Desmond
    Gananadha, Sivakumar
    Shorthouse, Amy
    Lee, Belinda
    Jain, Ankit
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [39] The clinical impact and analysis for neoadjuvant chemotherapy against borderline resectable pancreatic cancer: Gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel
    Takano, Shigetsugu
    Yoshitomi, Hideyuki
    Kagawa, Shingo
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Suzuki, Daisuke
    Sakai, Nozomu
    Mishima, Takashi
    Nakadai, Eri
    Ohtsuka, Masayuki
    CANCER RESEARCH, 2019, 79 (24)
  • [40] Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients
    Huang, Xiaolun
    Knoble, Jeanna L.
    Zeng, Ming
    Aguila, Fernando N.
    Patel, Tara
    Chambers, Lowell W.
    Hu, Honglin
    Liu, Hao
    PLOS ONE, 2016, 11 (12):
12345